[1] Wilhelm S, Tavares A J, Dai Q, et al. Analysis of nanoparticle delivery to tumours[J]. Nature Review Materials, 2016, 1(5):16014.
[2] Kim B Y S, Rutka J T, Chan W C W. Nanomedicine[J]. New England Journal of Medicine, 2010, 363(25):2434-2443.
[3] Petros R A, DeSimone J M. Strategies in the design of nanoparticles for therapeutic applications[J]. Nature Reviews Drug Discovery, 2010, 9(8):615-627.
[4] Allen T M, Chonn A. Large unilamellar liposomes with low uptake into the reticuloendothelial system[J]. Febs Letters, 1987, 223(1):42-46.
[5] Bangham A D, Standish M M, Watkins J C. Diffusion of univalent ions across the lamellae of swollen phospholipids[J]. Journal of Molecular Biology, 1965, 13(1):238.
[6] Langer R, Folkman J. Polymers for sustained-release of proteins and other macromolecules[J]. Nature, 1976, 263(5580):797-800.
[7] Yatvin M B, Kreutz W, Horwitz B A, et al. pH-sensitive liposomes:possible clinical implications[J]. Science, 1980, 210(4475):1253-1255.
[8] Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy:Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs[J]. Cancer Research, 1986, 46(12 Part 1):6387-6392.
[9] Barenholz Y. Doxil®-The first FDA-approved nano-drug:Lessons learned[J]. Journal of Controlled Release, 2012, 160(2):117-134.
[10] Ragelle H, Danhier F, Préat V, et al. Nanoparticle-based drug delivery systems:A commercial and regulatory outlook as the field matures[J]. Expert Opinion on Drug Delivery, 2016, 14(7):851.
[11] Danhier F. To exploit the tumor microenvironment:Since the EPR effect fails in the clinic, what is the future of nanomedicine[J]. Journal of Controlled Release, 2016, 244(Pt A):108-121.
[12] Al-Jamal W T, Kostarelos K. Liposomes:From a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine[J]. Accounts of Chemical Research, 2011, 44(10):1094-1104.
[13] Yi Y, Lin G, Chen S, et al. Polyester micelles for drug delivery and cancer theranostics:Current achievements, progresses and future perspectives[J]. Materials Science & Engineering C-Materials for Biological Applications, 2018, 83:218-232.
[14] Mi P, Wang F, Nishiyama N, et al. Molecular cancer imaging with polymeric nanoassemblies:From tumor detection to theranostics[J]. Macromolecular Bioscience, 2016, 17(1):1600305.
[15] Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery:Design, characterization and biological significance[J]. Advanced Drug Delivery Review, 2001, 47(1):113-131.
[16] Tibbitt M W, Dahlman J E, Langer R. Emerging frontiers in drug delivery[J]. Journal of the American Chemical Society, 2016, 138(3):704-717.
[17] Duncan R. Polymer conjugates as anticancer nanomedicines[J]. Nature Reviews Cancer, 2006, 6(9):688-701.
[18] Sparreboom A, Scripture C D, Trieu V, et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol)[J]. Clinical Cancer Research, 2005, 11(11):4136-4143.
[19] Wibroe P P, Ahmadvand D, Oghabian M A, et al. An integrated assessment of morphology, size, and complement activation of the PEGylated liposomal doxorubicin products Doxil®, Caelyx®, Doxorubicin, and SinaDoxosome[J]. Journal of Controlled Release, 2016, 221:1-8.
[20] Chen B, Li Y, Zhang X, et al. An efficient synthesis of ferumoxytol induced by alternating-current magnetic field[J]. Materials Letters, 2016, 170:93-96.
[21] Ma K, Sai H, Wiesner U. Ultrasmall sub-10 nm near-infrared fluorescent mesoporous silica nanoparticles[J]. Journal of the American Chemical Society, 2012, 134(32):13180-13183.
[22] Moran C H, Wainerdi S M, Cherukuri T K, et al. Size-dependent joule heating of gold nanoparticles using capacitively coupled radiofrequency fields[J]. Nano Research, 2009, 2(5):400-405.
[23] Pirollo K F, Chang E H. Does a targeting ligand influence nanoparticle tumor localization or uptake?[J]. Trends in Biotechnology, 2008, 26(10):552-558.
[24] Jain R K. Delivery of molecular and cellular medicine to solid tumors[J]. Advanced Drug Delivery Reviews, 2001, 46(1):149-168.
[25] Verma A, Uzun O, Hu Y, et al. Surface-structure-regulated cell-membrane penetration by monolayer-protected nanoparticles[J]. Nature Materials, 2008, 7:588-595.
[26] Hrkach J, Von Hoff D, Ali M M, et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile[J]. Science Translational Medicine, 2012, doi:10.11261scitranslmed.3003651.
[27] Mamot C, Ritschard R, Wicki A, et al. Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded antiEGFR immunoliposomes in advanced solid tumours:A phase 1 dose-escalation study[J]. The Lancet Oncology, 2012, 13(12):1234-1241.
[28] Stylianopoulos T, Jain R K. Design considerations for nanotherapeutics in oncology[J]. Nanomedicine Nanotechnology Biology & Medicine, 2015, 11(8):1893-1907.
[29] Matsumura Y, Gotoh M, Muro K, et al. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer[J]. Annals of Oncology, 2004, 15(3):517-525.
[30] Hamaguchi T, Matsumura Y, Nakanishi Y, et al. Antitumor effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts[J]. Cancer Science, 2010, 95(7):608-613.
[31] Von Hoff, D D, Mita M M, Ramanathan R K, et al. Phase I study of PSMA-targeted docetaxel-containing nanoparticle BIND-014 in patients with advanced solid tumors[J]. Clinical Cancer Research, 2016, 22(13):3157.
[32] Zuckerman J E, Gritli I, Tolcher A, et al. Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA[J]. PNAS, 2014, 111(31):11449-11454.
[33] Draz M S, Fang B A, Zhang P, et al. Nanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections[J]. Theranostics, 2014, 4(9):872-92.
[34] Alexis F, Pridgen E, Molnar L K, et al. Factors affecting the clearance and biodistribution of polymeric nanoparticles[J]. Molecular Pharmaceutics, 2008, 5(4):505-515.
[35] Perrault S D, Walkey C, Jennings T, et al. Mediating tumor targeting efficiency of nanoparticles through design[J]. Nano Letters, 2009, 9(5):1909-1915.
[36] Gu F, Zhang L, Teply B A, et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers[J]. PNAS, 2008, 105(7):2586-2591.
[37] Nel A E, Mädler L, Velegol D, et al. Understanding biophysicochemical interactions at the nano-bio interface[J]. Nature Materials, 2009, 8(7):543-557.
[38] Alizadeh A A, Aranda V, Bardelli A, et al. Toward understanding and exploiting tumor heterogeneity[J]. Nature Medicine, 2015, 21(8):846-853.
[39] Junttila M R, Sauvage F J D. Influence of tumour micro-environment heterogeneity on therapeutic response[J]. Nature, 2013, 501(7467):346-354.
[40] Toh Y C, Lim T C, Tai D, et al. A microfluidic 3D hepatocyte chip for drug toxicity testing[J]. Lab on A Chip, 2009, 9(14):2026.
[41] Huh D, Matthews B D, Mammoto A, et al. Reconstituting organ-level lung functions on a chip[J]. Science, 2010, 328(5986):1662.
[42] Albanese A, Lam A K, Sykes E A, et al. Tumour-on-a-chip provides an optical window into nanoparticle tissue transport[J]. Nature Communication, 2013, 4(10):2718.
[43] Choi S Y, Lin D, Gout P W, et al. Lessons from patient-derived xenografts for better in vitro modeling of human cancer[J]. Advanced Drug Delivery Reviews, 2014, 80:222-237.
[44] Sharpless N E, Depinho R A. The mighty mouse:Genetically engineered mouse models in cancer drug development[J]. Nature reviews Drug discovery, 2006, 5(9):741-754.
[45] Bertrand N, Wu J, Xu X, et al. Cancer nanotechnology:The impact of passive and active targeting in the era of modern cancer biology[J]. Advanced Drug Deliver Reviews, 2014, 66(24):2-25.
[46] Lin D, Wyatt A W, Xue H, et al. High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development[J]. Cancer Research, 2014, 74(4):1272.
[47] Rongvaux A, Willinger T, Martinek J, et al. Development and function of human innate immune cells in a humanized mouse model[J]. Nature Biotechnology, 2014, 32(4):364.
[48] Hubbard G K, Mutton L N, Khalili M, et al. Combined MYC activation and Pten loss are sufficient to create genomic instability and lethal metastatic prostate cancer[J]. Cancer Research, 2016, 76(2):283.
